十月 2026
scholar.google.com.pr
全球排名
- -
国家/地区排名
- -
品类排名
- -
显示 Similarweb 估计数据。
关联 GA4,公开验证您的网站指标
与您的成功同步
绑定 Google Analytics,验证您网站的流量及用户参与度指标
跳出率
75.55%
每次访问页数
1.89
平均访问时长
00:00:36
- 公司
- - -
- 行业
- - -
scholar.google.com.pr的 10 大竞争对手
在 十月 2026 与 scholar.google.com.pr 相似的前 10 名网站,按关键字流量、受众定位和市场重叠方面与 scholar.google.com.pr 的关联性排名
sciencedirect is the world's leading source for scientific, technical, and medical research. explore journals, books and articles.
跳出率
31.28%
每次访问页数
6.01
平均访问时长
00:07:55
Explore options for your family: the YouTube Kids app or a parent supervised account for older kids & teens on YouTube, all with built-in protections.
跳出率
23.61%
每次访问页数
11.07
平均访问时长
00:18:45
相似度评分
86%academia.edu is a place to share and follow research.
跳出率
61.51%
每次访问页数
2.35
平均访问时长
00:01:41
Access 160+ million publication pages and connect with 25+ million researchers. Join for free and gain visibility by uploading your research.
跳出率
46.91%
每次访问页数
3.59
平均访问时长
00:03:06
We perform a behavioral experiment of karma, a class of mechanisms for repeated resource allocation with attractive fairness and efficiency properties, in theory. Individuals in these mechanisms bid non-tradable credits that flow from resource consumers to yielders. Human subjects recruited on Amazon MTurk are repeatedly and randomly paired to bid karma according to time-varying individual urgency to acquire resources. Treatments varied in the urgency process (frequent moderate versus sporadic high urgency) and the richness of the bidding scheme (binary versus full range). Benchmarked against random allocation, karma achieves an (almost) Pareto improvement, despite subjects deviating from the theoretically optimal Nash bidding policy: maximum improvement is attained by subjects deviating by up to one karma bid unit on average, and positive improvement with deviations of up to 3-4 units. These findings hold across all treatments, among which no significant differences are found, with the exception of the sporadic high urgency process with binary bidding being (weakly) favorable. They offer behaviorally robust lower bounds for karma's expected performance in human populations and guide its future implementation.
- 公司
- - -
- 行业
- - -
跳出率
39.23%
每次访问页数
3.17
平均访问时长
00:04:08
相似度评分
73%indexingmethod_automated - Search Results - PubMed
- 公司
- - -
- 行业
- - -
全球排名
- -
国家/地区排名
- -
品类排名
- -
跳出率
- -
每次访问页数
- -
平均访问时长
- -
the world’s largest collection of open access research papers
- 公司
- - -
- 行业
- - -
跳出率
26.98%
每次访问页数
5.13
平均访问时长
00:04:27
相似度评分
65%Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. Methods In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. Results A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. Conclusions A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 mont
- 公司
- - -
- 行业
- - -
跳出率
24.78%
每次访问页数
3.71
平均访问时长
00:01:07
Learn more about our institutional models for librarians and the benefits for researchers.
跳出率
61.54%
每次访问页数
1.75
平均访问时长
00:01:42
相似度评分
61%DOAJ is a unique and extensive index of diverse open access journals from around the world, driven by a growing community, committed to ensuring quality content is freely available online for everyone.
- 公司
- - -
- 行业
- - -
跳出率
19.35%
每次访问页数
4.43
平均访问时长
00:01:51
相似度评分
59%scholar.google.com.pr在 十月 2026 的前五名竞争对手是:sciencedirect.com、youtube.com、academia.edu、researchgate.net等。
根据 Similarweb 的月访问量数据,scholar.google.com.pr 在 十月 2026 的头号竞争对手是 sciencedirect.com。与 scholar.google.com.pr 相似度排名第二的网站是 youtube.com,排名第三的是 academia.edu。
在 十月 2026,researchgate.net 被评为与 scholar.google.com.pr 相似度第四高的网站,arxiv.org 位居第五。
进入前十名榜单的其他五家竞争对手分别是 pubmed.ncbi.nlm.nih.gov、core.ac.uk、scienceopen.com、plos.org 和 doaj.org。
